CD274 and colorectal carcinoma: This prompted a post-hoc analysis of the CRC cohort of COSMIC-021 trial which showed that cabozantinib plus atezolizumab (anti-PD-L1) also had more favorable response rates (25% vs. 0%), mPFS (5.8 vs. 2.7 months), and median OS (16.7 vs. 8.7 months) in patients with RAS wild type versus mutant pMMR/MSS metastatic CRC52.